Uganda Brings Life-Saving Sickle Cell Care to Local Clinics

Thousands of Ugandan children with sickle cell disease will soon get life-saving treatment in their own communities instead of traveling hours to distant hospitals.

The Ministry of Health announced it will bring sickle cell care to Health Centre III facilities nationwide while securing a locally produced supply of Hydroxyurea, the key drug that manages the genetic blood disorder. For families in rural areas, this means the difference between accessible care and watching their children suffer through preventable crises.

Uganda currently faces a staggering burden: 20,000 babies are born with sickle cell disease every year, and more than half die before their sixth birthday. The country ranks fourth among African nations for sickle cell cases, with some regions showing prevalence rates as high as 15 percent.

The tragedy often starts with late diagnosis. Most children aren't screened at birth and only reach doctors after developing severe, sometimes irreversible complications during pain crises.

Dr. Diana Atwine, Permanent Secretary at the Ministry of Health, explained that early screening and consistent care dramatically change outcomes. "When a child is screened at birth and linked to care consistently, there is a higher chance of survival, limited complications and a normal life," she said.

The breakthrough came through partnering with Cipla Quality Chemical Industries Limited to manufacture Hydroxyurea locally. Clinical trials show the medication significantly reduces complications, improves oxygen circulation, and enhances quality of life for patients.

Local production solves multiple problems at once: it ensures reliable supply, eliminates costly imports, prevents medication shortages, and reduces foreign exchange costs. Uganda also launched locally manufactured rapid diagnostic tests, making screening faster and more accessible.

The Ripple Effect

The changes reach far beyond individual patients. Mulago National Referral Hospital currently diagnoses about 40 new sickle cell cases every week, representing just a fraction of the true national burden due to limited testing capacity.

By deploying doctors to Health Centre III facilities and strengthening newborn screening programs, Uganda is building a system where every child can be tested at birth and receive treatment close to home. Families will no longer need to choose between expensive travel to distant hospitals or managing severe pain crises without medical support.

The shift toward local pharmaceutical production also strengthens Uganda's healthcare independence. Rather than relying on unpredictable international supply chains, the country now controls access to essential medications for one of its most vulnerable populations.

For the children born with sickle cell disease this year and every year forward, a normal childhood is finally within reach.